|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||21.90|
|Dividend & Yield||1.03 (3.23%)|
|1y Target Est||N/A|
In the first half of 2017, Roche’s (RHHBY) Esbriet reported revenues of CHF 418.0 million, which reflected a ~16.0% growth on a YoY basis.
In July 2017, the EC's CHMP recommended a positive opinion for Roche’s (RHHBY) Tecentriq as a monotherapy for the treatment of adults with metastatic NSCLC previously treated with chemotherapy.
In the first half of 2017, Roche’s (RHHBY) Tecentriq reported revenues of CHF 237.0 million. In that period, the US market for Tecentriq generated revenues of CHF 229.0 million.